Expanding the feasibility of nephron-sparing surgery: time for a paradigm shift?
BJU Int
.
2019 May;123(5):746-748.
doi: 10.1111/bju.14657.
Authors
Alessandro Veccia
1
2
,
Georgi Guruli
1
,
Ithaar Derweesh
3
,
Riccardo Autorino
1
Affiliations
1
Division of Urology, VCU Health System, Richmond, VA, USA.
2
Division of Urology, ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy.
3
Department of Urology, Moores UCSD Cancer Center, University of California San Diego School of Medicine, La Jolla, CA, USA.
PMID:
31008560
DOI:
10.1111/bju.14657
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Axitinib*
Feasibility Studies
Humans
Kidney Neoplasms / surgery*
Nephrectomy
Nephrons
Substances
Axitinib